← Back to Clinical Trials
Recruiting NCT05747365

Role of Endocrine Disruptors in Thyroid Cancer

Trial Parameters

Condition Endocrine Disruptor Chemicals
Sponsor Istituto Auxologico Italiano
Study Type OBSERVATIONAL
Phase N/A
Enrollment 222
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-07-12
Completion 2023-04-30
Interventions
Blood and urine diagnostic evaluation

Brief Summary

the relationship between human exposure to EDCS and TC is poorly investigated and still unclear. The aim of this study is to evaluate the possible role of old and new generation endocrine disruptors in thyroid cancer. The primary aim is to evaluate the difference in the average levels of the main endocrine disruptors (PFAS, including: PFOA, PFOS, PFDA, PFUnA, PFHpS and possibly subsequently other categories, such as bisphenols, phthalates, parabens, PCBs, flame retardants) between patients with and without a diagnosis of thyroid cancer through highly sensitive, selective and precise mass spectrometry methods, such as liquid chromatography combined with tandem mass spectrometry (LC-MS / MS). The secondary aim is to evaluate the relationship between the concentrations of endocrine disruptors and some anamnestic variables studied (for example the type of diet, the use of personal care products).

Eligibility Criteria

Inclusion Criteria: * patients with a diagnosis of thyroid cancer in the last 5 years (arm A) * patients without a diagnosis of thyroid cancer will match patients included in arm A Exclusion Criteria: * subjects under 18 years old * patients unable to sign the informed consent or questionnaires

Related Trials